UPDATE: Sequenom, GSK Team to Create SNP Assay Portfolio | GenomeWeb

UPDATE: Sequenom, GSK Team to Create SNP Assay Portfolio

Aug 29, 2001

NEW YORK, Aug. 29 – Sequenom has begun the first phase of a research partnership with British drug giant GlaxoSmithKline to create a human genome-wide SNP assay portfolio to help them identify genes responsible for disease states and drug reaction, the companies said on Wednesday.

The deal calls for GlaxoSmithKline to be given access to Sequenom’s SNP assay portfolio. The pharmaceutical company then plans to select SNP candidates for genome-wide association studies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Laureates Warn Against Hard Brexit

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

For All

Vox reports on inequities in genetic research and efforts to address them.

Lawrence Krauss to Retire Following Sexual Misconduct Allegations

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

This Week in PNAS

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.